Uhlmann Erik J, Eby Charles S
Division of Laboratory Medicine, Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
Curr Opin Hematol. 2004 May;11(3):198-204. doi: 10.1097/01.moh.0000135405.29702.3c.
THE PURPOSE OF THIS REVIEW: The purpose of this review is to summarize the safety and efficacy of recombinant activated factor VII in diverse clinical settings based on recent published anecdotal experiences and early results from prospective trials.
Recombinant activated factor VII is increasingly being used for off-label treatment and prophylaxis of bleeding in non-hemophiliac patients. Case reports would suggest that recombinant activated factor VII is an efficacious and safe "universal hemostatic agent". To date, results of several randomized control trials investigating recombinant activated factor VII in non-hemophiliacs have been published as abstracts, supporting recombinant activated factor VII safety, but not its efficacy.
Until the results of additional prospective trials are available, clinicians, who manage patients with challenging hemostatic complications, and transfusion medicine specialists should collaborate to develop local policies for off-label utilization of recombinant activated factor VII.
本综述的目的:本综述的目的是根据近期发表的轶事性经验和前瞻性试验的早期结果,总结重组活化凝血因子 VII 在不同临床环境中的安全性和有效性。
重组活化凝血因子 VII 越来越多地被用于非血友病患者出血的标签外治疗和预防。病例报告表明重组活化凝血因子 VII 是一种有效且安全的“通用止血剂”。迄今为止,几项在非血友病患者中研究重组活化凝血因子 VII 的随机对照试验结果已作为摘要发表,支持重组活化凝血因子 VII 的安全性,但不支持其有效性。
在获得更多前瞻性试验结果之前,处理具有挑战性止血并发症患者的临床医生和输血医学专家应合作制定重组活化凝血因子 VII 标签外使用的当地政策。